ReviewCalcified tissue international2026
The Role of Plastin in Bone, Cartilage, and Related Diseases.
Review in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The plastin family (PLS1, PLS2, PLS3) comprises highly conserved actin-binding proteins (ABPs) that regulate cytoskeletal dynamics by cross-linking actin microfilaments and play key roles in bone and cartilage development, homeostasis, and disease. PLS1 primarily stabilizes tight actin bundles in epithelial brush-border microvilli and has also been reported to support osteoblast differentiation via regulating intracellular Ca2+ homeostasis. In bone, PLS3 mutations lead to X-linked osteoporosis through mechanisms involving the inhibition of the WNT pathway, activation of TH17 cell differentiation, and disorders of osteogenesis mediated by the neutrophil extracellular trap (NET) pathway. Meanwhile, PLS2 promotes osteoclast sealing ring assembly and drives bone resorption via Ser-5/Ser-7 phosphorylation. In cartilage, PLS3 is highly expressed on the surface layer of osteoarthritis (OA) patients, with expression levels positively correlating with degeneration severity, possibly involved in chondrocyte hypertrophy in response to mechanical loading. Pathologically, PLS3 deficiency directly causes early-onset osteoporosis and increased fracture risk, while PLS2 plays a dual role in cancer metastasis and inflammation. Targeting plastin, such as inhibiting PLS2 phosphorylation or supplementing PLS3 mRNA, offers potential new strategies for treating hyperresorption and hereditary bone diseases.
Indexed as
Identifiers
42060122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.